Site search
2813 results for '' found
CN008-0003: A Phase 2, Randomized, Double-blind, Placebo-controlled, Multicenter Study Assessing the Efficacy, Safety and Tolerability of an Anti-MTBR Tau Monoclonal Antibody, in Participants wit
CN008-0003: A Phase 2, Randomized, Double-blind, Placebo-controlled, Multicenter Study Assessing the Efficacy, Safety and Tolerability of an Anti-MTBR Tau Monoclonal Antibody, in Participants wit
/
A Phase 3, Prospective, Open-Label, Multisite, Extension of Phase 3 Studies To Assess the Long-Term Safety and Tolerability of Soticlestat as Adjunctive Therapy in Subjects With Dravet Syndrome o
A Phase 3, Prospective, Open-Label, Multisite, Extension of Phase 3 Studies To Assess the Long-Term Safety and Tolerability of Soticlestat as Adjunctive Therapy in Subjects With Dravet Syndrome o
/
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy, Safety, and Tolerability of Soticlestat as Adjunctive Therapy in Pediatric and Adult Su
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy, Safety, and Tolerability of Soticlestat as Adjunctive Therapy in Pediatric and Adult Su
/
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy, Safety, and Tolerability of Soticlestat as Adjunctive Therapy in Pediatric and Young Ad
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy, Safety, and Tolerability of Soticlestat as Adjunctive Therapy in Pediatric and Young Ad
/
A Phase 3, Randomized, Multicenter, Double-Blind, Placebo- and Active Comparator-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of TAK-279 in Subjects With Moderate-to-Severe
A Phase 3, Randomized, Multicenter, Double-Blind, Placebo- and Active Comparator-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of TAK-279 in Subjects With Moderate-to-Severe
/
A Phase 3, Multicenter, Open-Label Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of TAK-279 in Subjects with Moderate-to-Severe Plaque Psoriasis (NCT06550076)
A Phase 3, Multicenter, Open-Label Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of TAK-279 in Subjects with Moderate-to-Severe Plaque Psoriasis (NCT06550076)
/
A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate Efficacy and Safety of Mezagitamab Subcutaneous Injection in Participants with Chronic Primary Immune Thrombocytopenia (N
A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate Efficacy and Safety of Mezagitamab Subcutaneous Injection in Participants with Chronic Primary Immune Thrombocytopenia (N
/
A Phase 1 study of TAS-116 (pimitespib) in combination with imatinib in patients with advanced gastrointestinal stromal tumor (NCT05245968)
A Phase 1 study of TAS-116 (pimitespib) in combination with imatinib in patients with advanced gastrointestinal stromal tumor (NCT05245968)
/
The Syncope-Stopper study: comparison of upfront pacing with standard care for high-risk patients with unexplained syncope. (ACTRN12622001553763)
The Syncope-Stopper study: comparison of upfront pacing with standard care for high-risk patients with unexplained syncope. (ACTRN12622001553763)
/
Symptom monitoring WIth Feedback Trial (SWIFT) (ACTRN12620001061921)
Symptom monitoring WIth Feedback Trial (SWIFT) (ACTRN12620001061921)
/